PRIMORIS SERVICES CORPORATION ANNOUNCES PIPELINE AWARDS VALUED OVER $100 MILLION
DALLAS, April 02, 2020 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”) today announced new […]
TSX News -
Helix BioPharma Corp. Provides Corporate Update
RICHMOND HILL, Ontario, April 02, 2020 (GLOBE NEWSWIRE) — Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology […]
FTI Consulting Releases 2020 Survey of U.S. Loan Market
WASHINGTON, April 02, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today released the findings of its 2020 U.S. […]
LITTLE GREEN PHARMA AND ELIXXER, LTD. COVID-19 BUSINESS UPDATE
MONTREAL, April 02, 2020 (GLOBE NEWSWIRE) — ELIXXER, LTD. (TSX.V: ELXR OTCQB: ELIXF GR: 2LQA) (“ELXR” or the “Company”) is pleased […]
FLYHT Provides First Quarter 2020 Update and Schedules Fourth Quarter and Fiscal 2019 Conference Call
CALGARY, Alberta, April 02, 2020 (GLOBE NEWSWIRE) — FLYHT Aerospace Solutions Ltd. (TSX-V: FLY) (OTCQX: FLYLF) (the “Company” or “FLYHT”) […]
BioCryst Appoints Anthony Doyle Chief Financial Officer
RESEARCH TRIANGLE PARK, N.C., April 02, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of […]
Applied Therapeutics Announces IND and Investigator-Initiated Studies of AT-001 in Critical COVID-19 Patients
New AT-001 IND opened with FDA for acute lung inflammation and cardiomyopathy in critical COVID-19 patientsHospitals in New York City […]
Oportun Provides COVID-19 Operational Business Update
SAN CARLOS, Calif., April 02, 2020 (GLOBE NEWSWIRE) — Oportun Financial Corporation (“Oportun” or the “Company”) (Nasdaq: OPRT) today provided […]
Fulcrum Therapeutics Provides Business Update on Impact of COVID-19
CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives […]
AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases
Seven presentations by AC Immune and its partners at AAT-AD/PD™New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates A […]
